+44 (0) 1223 755950
+1 832 327 7413
Visilizumab
REQUEST MORE INFO
Catalogue No: abx831032
Price:
US$464.00
(Size: 100 µg)
Reviews: 
(0 Publications and Reviews)
(0 Publications and Reviews)
Click on the image to see the image legend
Visilizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD3E, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Visilizumab has been investigated for the treatment of Ulcerative Colitis.
Research Articles on CD3E
| Target | CD3E |
| Clonality | Monoclonal |
| Reactivity | Human |
| Expression | Recombinant |
| Tested Applications | ELISA, WB |
| Host | Human |
| Recommended dilutions | Optimal dilutions/concentrations should be determined by the end user. |
| Conjugation | Unconjugated |
| Isotype | IgG2-ND |
| Form | Liquid |
| Purity | > 95% |
| Purification | Purified from cell culture supernatants by Protein A/G chromatography. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Buffer | 0.01 M PBS. pH 7.4. |
| CAS Number | 219716-33-3 |
| Concentration | Batch-dependent, typically between 0.5-2.0 mg/ml. |
| Availability | Shipped within 7-12 working days. |
| Note | This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use. |